Lutris Pharma Secures $30 Million Funding for Development of Topical Gel to Alleviate EGFR Inhibitor-Induced Rashes

Lutris Pharma raises $30 million to develop LUT014, a topical gel designed to reduce rashes caused by EGFR inhibitors in cancer treatment, with the aim of improving patients' quality of life and treatment adherence.